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Medical Symptoms Associated with Tobacco Smoking with and without 
Marijuana Abuse among Crack Cocaine-dependent Patients 
 
Ashwin A. Patkar, M.D., Vikas Batra, M.D., Paolo Mannelli, M.D., 
Sarah Evers-Casey, M.P.H., Michael J. Vergare, M.D., 
Frank T. Leone, M.D., M.S. 
 
Despite the widespread use of tobacco and marijuana by cocaine abusers, it remains unclear 
whether combined tobacco and marijuana smoking is more harmful than tobacco smoking alone 
in cocaine abusers. We investigated the differences in medical symptoms reported among 34 
crack cocaine abusers who did not smoke tobacco or marijuana (C), 86 crack cocaine abusers 
who also smoked tobacco (C + T), and 48 crack abusers who smoked both tobacco and 
marijuana (C + T + M). Medical symptoms were recorded using a 134-item self-report 
instrument (MILCOM), and drug use was assessed using the Addiction Severity Index (ASI). 
After controlling for clinical and demographic differences, the C + T + M group reported 
significantly more total symptoms on the MILCOM as well as on the respiratory, digestive, 
general, and nose=throat subscales than the C + T or C groups. The C + T group reported 
higher total and respiratory and nose=throat symptoms than the C group. However, the C group 
had the highest number of mood symptoms among the three groups. The C + T and C + T + M 
groups were comparable in number of cigarettes smoked and ASI scores. Although tobacco 
smoking is associated with higher reports of medical problems in crack abusers, smoking both 
marijuana and tobacco seems to be associated with greater medical problems than smoking 
tobacco alone. Tobacco smoking was not related to changes in cocaine use. Also, marijuana 
smoking does not appear to be associated with a reduction in tobacco or cocaine use. (Am J 
Addict 2005;14:43–53) 
 
 
Although adult tobacco use has declined in the recent years, certain population groups, 
particularly those with substance dependence, have shown no appreciable reduction. (1–3)  The 
prevalence of tobacco smoking in substance abusers is found to be 4–5 times higher than in the 
general population, (4–5) with smoking rates of 75–80% reported among cocaine abusers. 3,(6–
8) The health hazards of tobacco use among substance abusers, including premature death, have 
been well documented. (9,10) For example, Hurt et al. (11) found that individuals treated for 
substance dependence continued to have a high risk of developing tobacco-related diseases and 
were more likely to die from tobacco- related causes than illnesses related to their primary 
substance of abuse. 
The National Household Survey on Drug Abuse (NHSDA) (12) found that marijuana is the most 
commonly used illicit drug in the U.S., with a prevalence rate of 5.4%. Marijuana users comprise 
nearly 75% of all illicit drug users in the U.S.; about 55% use mostly marijuana and about 20% 
use marijuana along with another illicit drug. (12) Cocaine abusers in particular have been found 
to have very high rates of marijuana use. For example, in a study of 228 crack cocaine abusers, 
Gorelick et al. 6 found that 17.5 % of patients had smoked only marijuana and 61% smoked 
tobacco and marijuana. Both tobacco and marijuana are considered to be gateway drugs for 
cocaine use as their use almost always precedes the use of cocaine. (13–15) Further, tobacco and 
marijuana use are closely associated. Among marijuana smokers, approximately 75% also smoke 
tobacco. (16) Also, analysis of the NHSDA data showed that tobacco smokers are seven times 
more likely to use marijuana than those who do not smoke tobacco. (12,17,18) The impact of 
marijuana smoking on tobacco use remains unclear. While several studies have not found a 
decrease in tobacco smoking with concomitant marijuana use, (19,20) a small study of eight 
patients reported that marijuana smoking was related to a significant reduction in tobacco 
smoking. (21) In contrast, in a large sample of 431 subjects, Ford et al. (22) reported that use of 
marijuana at baseline strongly correlated with continued smoking even after thirteen years. Since 
the first Surgeon General’s report (23) on the harmful consequences of tobacco use was 
published over 35 years ago, the adverse medical consequences of tobacco smoking have been 
well established. Smokers have a ten-fold increased risk of developing lung cancer and show a 
2–4 times greater risk of dying from coronary heart disease compared to non-smokers. (24) 
Furthermore, smoking is found to account for about 90% of cases of emphysema, (25) and 
maternal smoking has been linked to low birth weight babies and stillbirth. (26) Studies have 
also shown that chronic, habitual smoking of marijuana has adverse health effects that may be 
com- parable or possibly more serious than tobacco. (27–29) Marijuana smoke contains several 
of the carcinogenic and irritant compounds that are found in tobacco smoke. (30) In addition, 
compared to smoking tobacco, smoking marijuana is associated with a nearly five-fold greater 
increase in blood carboxyhemoglobin levels, an approximately three-fold increase in the amount 
of tar inhaled, and retention in the respiratory tract of one-third more tar. (31) Large scale studies 
have found that independent of the effects of tobacco, marijuana smoking is associated with 
increased risk of bronchitis, head and neck cancers, and cardiovascular and neuropsy- chiatric 
problems. (32–34) The data on the medical effects of smoking both marijuana and tobacco in the 
general population are sparse and inconsistent. For example, Gong et al. (35) reported no 
statistically significant differences in respiratory symptoms and lung functions between 
marijuana smokers, tobacco smokers, and marijuana plus tobacco smokers. In contrast, Sherman 
et al. (36) found adverse effect of combined marijuana and tobacco smoking on lung function 
tests such as diffusion capacity. Other studies suggest that the combination of marijuana and 
tobacco smoking may be more harmful than smoking marijuana or tobacco alone, as the 
combination leads to more inflammation in the lungs (37) and DNA damage. (38) Although 
medical problems due to the use of specific substances are well documented, there are few 
studies that have examined the possible additive effects of tobacco and marijuana smoking upon 
medical symptoms of substance abusers. We have previously reported that substance abusers 
who smoke tobacco report more medical symptoms when compared to non-smokers; however, 
these effects seemed to differ between cocaine-, alcohol-, and opiate-dependent patients. (39) In 
the present study, we investigated whether combined tobacco and marijuana smoking is more 
harmful than tobacco smoking alone in crack cocaine abusers. The sample recruited for this 
study was different from our previous work.  
 
 
 
 
Methods 
 
Subjects 
As a part of a National Institute on Drug Abuse-supported study on biological markers in 
cocaine addiction, 168 cocaine- dependent subjects were recruited from a publicly funded, 
university-affiliated, intensive outpatient cocaine treatment program that serves a predominantly 
inner-city population in Philadelphia. The study was approved by the Institutional Review Board 
of Thomas Jefferson University, and written informed consent was obtained from all subjects. 
Over 95% of cocaine- dependent patients smoked crack cocaine; therefore, only patients 
smoking crack cocaine were included in the study. Crack cocaine users were included if they 
were diagnosed with primary cocaine dependence in accordance with DSM-IV criteria. (40) 
Marijuana users were included if their urine screens at admission were positive for marijuana and 
they met DSM-IV criteria for current marijuana abuse or dependence. Tobacco smokers who 
fulfilled DSM-IV criteria for nicotine dependence and whose urine drug screens tested positive 
for nicotine were included. Patients who used other illicit drugs or alcohol were included only if 
their drug of choice was crack cocaine and they were not dependent on illicit drugs (except 
marijuana). Patients with past or present comorbid schizophrenia or bipolar disorder were 
excluded. 
 
 
Assessments 
 
Subjects received a standard set of assessments as part of the intake process. This 
included demographic data, addiction and medical history, urine drug screens, and physical 
examination. The subjects also completed the MILCOM, (41) a 134-item self- report 
questionnaire about medical symptoms relating to seventeen body organ systems: head=neck, 
eyes, ears, mouth, nose=throat, respiratory, cardiovascular, gastrointestinal, urinary, 
musculoskeletal, male genital, female genital, obstetric, skin, neurological, mood, and general. 
The MIL-COM is easy to administer and free of jargon, and it takes about fifteen minutes to 
complete. It is therefore a convenient screening tool for medical symptoms in an outpatient 
setting. We did not include the gender specific scales (male genital, female genital, obstetric) in 
our analyses and omitted items on traveling abroad and wearing seat belts, bringing the total 
number of endorsable items in the study to 108. Severity of substance use was assessed using the 
Addiction Severity Index (ASI), (42) a forty-minute structured interview assessing the severity 
and patterns of drug and alcohol use and impairment in employment, medical, legal, 
family=social, and psychiatric domains of functioning. For each problem area, it provides a 
subjective severity rating and a more objective composite score. It has been widely employed in 
clinical and research settings. Depressive symptoms were rated using the Beck Depression 
Inventory (BDI), (43) a 21-item, self-report questionnaire that assesses depressive 
symptomatology and requires about ten minutes to complete. 
 
 
 
Assessment of Tobacco, Crack and Marijuana Use 
 
 
 
Individuals were initially assessed to determine whether they smoked tobacco. For 
smokers, the number of cigarettes smoked per day was recorded. Patients who had not smoked in 
the previous twelve months were considered former smokers, while individuals who had smoked 
fewer than 100 cigarettes in their lifetime were considered nonsmokers. The amount of crack use 
was recorded in grams per day, frequency as days per week, and duration as years of regular use. 
The amount of marijuana use was recorded as joints per day and per week, and duration as years 
of regular use. Joint years of use was defined as average number of joints per smoking day 
multiplied by years of use. 
 
Data Analysis 
 
Subjects were divided into cocaine alone (C), cocaine and tobacco (C þ T), and cocaine, 
marijuana, and tobacco (C þ T þ M) groups. Chi-square tests, independent t-tests (two-tailed), 
and one way Analysis of Variance (ANOVA) were used as appropriate to examine demographic 
and clinical differences. The three patient groups were then compared with respect to the number 
of symptoms endorsed in total as well as on each of the fourteen MILCOM scales using ANOVA 
and Analysis of Covariance (ANCOVA), controlling for clinical and demographic differences. 
For this purpose, the data on clinical and demographic variables were used as a covariate while 
comparing medical symptoms across the three patient groups using ANCOVA. When 
appropriate, post-hoc Scheffe Tests (44) were conducted to tease apart significant effects. 
Relationships between the number of cigarettes and joints smoked and medical symptoms were 
examined by Pearson product moment correlation. The approach to deal with potential Type I 
error associated with multiple tests (fourteen subscales of MILCOM) was to initially perform a 
test of overall significance using total scores on MILCOM, as recommended by Cohen and 
Cohen. 45 Only in the case of a significant result ( p < .05) or trend ( p < .10) for the total scale 
were tests of significance performed for the subscales.  
 
 
RESULTS 
 
Subjects 
Out of 258 crack cocaine-dependent patients screened, a total of 168 subjects met the inclusion 
criteria and were enrolled in the study. Excluded subjects were: eight patients with current major 
psychiatric disorder, 41 patients who also met criteria for alcohol=other illicit drug dependence 
(except marijuana), 32 marijuana smokers who did not meet the criteria for abuse= dependence, 
and nine patients who were intermittent tobacco smokers and/or primarily smoked cigars or 
chewed tobacco. The 168 subjects included in the study were: 34 crack cocaine abusers who did 
not smoke tobacco or marijuana (C), 86 crack cocaine abusers who also smoked tobacco (C þ T), 
and 48 crack abusers who smoked both tobacco and marijuana (C þ T þ M). The sample included 
114 (67.8%) men and 54 (32.2%) women; 142 (84.5%) were African-American, 20 (11.9%) 
were Caucasian, and 6 (3.6%) were Hispanic. The demographic and clinical differences between 
the three groups are summarized in Table 1. As seen in Table 1, the marijuana- smoking patients 
were significantly younger (as expected) than those who used tobacco and cocaine or cocaine 
alone, and the C + T + M patients had a shorter duration of cocaine use than the C + T and C 
groups. Those who concurrently used tobacco and marijuana reported lower scores on the Beck 
Depression (BDI) than those who used cocaine alone. Amount of cocaine use, ASI scores, and 
number of cigarettes smoked did not differ between the three groups. We examined whether 
medical symptoms among our subjects were related to demographic variables. The results 
showed that age, gender, or race were not significantly correlated with the total number of 
medical symptoms on the MILCOM (r < .12, v 2 < 1.46, p > .05 in each case). 
 
Tobacco and Marijuana Smoking Patterns Among Cocaine Abusers 
 
One hundred and thirty four (79.8%) subjects were current tobacco smokers. On average, 
patients smoked nearly sixteen cigarettes per day for about 24 years. The proportion of men 
(78.6%) and women (82.1%) who were smokers did not differ significantly. Similarly, no 
significant differences were found between African-American (79.2%) and Caucasian (80.9%) 
subjects with respect to rate of smoking (v2 = 0.31, df = 1, p > .05) and number of cigarettes 
smoked per day (AA = 15.4, Caucasians = 16.9; t = 1.31, df = 160, p > .05). Forty eight (28.6 %) 
of cocaine-dependent patients smoked marijuana regularly over a year. The average number of 
marijuana joints smoked per week was eight, the average frequency was three times 
a week, the number of joints on smoking days averaged 2.5, and the average duration of regular 
use was fifteen years. The mean age of beginning regular marijuana use was about seventeen 
years. There were no significant gender or ethnic differences in marijuana use (v 2 < 1.48, df = 1, 
p > .05 in each case). The pattern of marijuana use in our sample shows certain similarities as 
well as differences when compared to data in the literature. For example, in a study of 228 
cocaine smokers from the Los Angeles Area, Gorelick et al. 6 reported that 61% had a lifetime 
history of both marijuana and tobacco use, 17.5% smoked marijuana only, and 17% smoked 
tobacco only. Although these rates of marijuana use seem higher than that observed in our 
sample, we examined current rates in contrast to Gorelick et al., who studied lifetime rates. 
While the mean of age of onset (17.7 years) and average amount of use (6.4 joints per week and 
2.2 joint per smoking day) of marijuana use in this study were similar to that seen in our subjects, 
cocaine users in Gorelick et al.’s study had a higher joint year history (average 50.7 years), 
reflecting heavier use compared to our sample (average 37 years). 
 
 
 
 
Symptom Differences among Cocaine, Cocaine and Tobacco, and Cocaine, 
Tobacco and Marijuana Groups 
 
 
Analysis of variance revealed a significant difference in the total symptoms reported by 
the three groups, with the C + T + M smoking patients reporting the highest number of 
symptoms (F(2,166) = 6.06, p < .01). As shown in Table 2, the C + T + M patients also reported 
the highest number of symptoms on the respiratory, nose–throat, digestive and general subscales; 
however, the cocaine patients reported the highest symptoms on the mood scale. Since the C 
patients were significantly younger and had higher depression (BDI) scores than C + T or C + T 
+ M patients, we examined whether age or mood symptoms could have affected the level of 
health complaints. For this purpose, the data were reanalyzed, covarying for age and BDI scores. 
The ANCOVA analysis showed that the between-group differences in MILCOM scores 
continued to remain significant after controlling for age and depression (F [2,164] ranged from 
5.83 to 3.42, p < .01). In fact, cocaine users who smoked marijuana and tobacco, despite 
experiencing less depressive symptoms and being younger, reported more medical problems than 
individuals who only smoked cocaine. Therefore, mood symptoms or age did not appear to 
explain the differences in reporting of medical problems among the three groups. We also 
examined whether alcohol use affected the findings, using ASI alcohol composite scores as a 
covariate. The analysis showed that the direction and strength of differences in total MILCOM 
symptoms between the three groups remained unchanged after controlling for alcohol (F[2,164] 
= 6.39, p < .01). 
Post hoc (Scheffe) tests were then carried out to detect differences among the three drug groups. 
As summarized in Table 2, the C + T + M group reported significantly more symptoms on the 
total scale as well as on the respiratory, digestive, general, and nose–throat subscales than the C 
+ T or C groups, while the C + T group reported higher total and respiratory and nose throat 
symptoms than the C group (F ranged from 6.06 to 3.48, p <.01– <.05). However, the C group 
reported higher mood symptoms than the C + T and the C + T + M group. Among patients who 
smoked tobacco (n =134), we examined the correlation between pack years of smoking (packs 
per day x years of smoking; mean, 36 years) and MILCOM scores after controlling for marijuana 
use using tests of partial correlation. While a trend was observed between pack years and total 
symptoms (r = .23, p = .08), a significant positive correlation was obtained between pack years 
and scores on the respiratory (r = .29, p < .05) and nose–throat scales (r = .28, p < .01). No 
significant correlations were obtained with scores on the remaining MILCOM systems (all r < 
0.18, p > .05). However, no significant correlation was observed between joint years of 
marijuana use (joints per day x years of use; mean, 37.5 years) and total or subscale scores on the 
MILCOM (all r < .11, p > .05) among marijuana smokers (n = 48) after controlling for tobacco 
use. Twenty six (15.4%) of patients had a history of chronic medical diseases, such as asthma, 
hypertension, and diabetes, or were taking medications for their medical conditions. One patient 
had tested positive for HIV infection and hepatitis exposure, and two patients had a history of 
only hepatitis exposure. There were no significant differences in the history of medical disease 
among C patients (n = 4, 11.7%), C + T patients (n = 16, 18.6%), and the C + T + M patients (n 
= 6, 12.5%) (v 2 = 2.31, df = 2, p = .19). 
 
DISCUSSION 
 
Our results show that crack cocaine abusers who smoke tobacco report more medical symptoms 
than nonsmokers. Moreover, the regular use of both marijuana and tobacco is associated with 
higher reports of medical symptoms than the use of tobacco alone in this population. The 
findings suggest that while tobacco use is associated with greater medical problems, concomitant 
use of tobacco and marijuana may have additive harmful effects in crack cocaine abusers. 
Demographic and clinical variables such as severity and pattern of cocaine use were unlikely to 
be confounders because the three patient groups were largely similar across these measures. 
Also, the higher depression scores in cocaine patients are not likely to have led to under- 
reporting of symptoms because depressed patients generally report higher, not lower, somatic 
symptoms than non-depressed patients. Furthermore, we statistically controlled for the effect of 
depression on the relationship between the primary and dependent variables. It is also worth 
noting that significant differences between tobacco and marijuana users and nonusers were 
observed across respiratory, nose–throat, and gastrointestinal systems, organ systems that have 
been reported to be more commonly affected by both tobacco and marijuana smoking. (27,29) 
Consistent with the literature, (46) we found a significant correlation between the pack years of 
tobacco smoking and respiratory and nose–throat symptoms in a crack-using population. 
Because cocaine abusers tend to smoke heavily and have lower quit rates than the general 
population, it is likely that their risk for developing tobacco-related medical diseases is 
comparable to (if not higher than) the general population. Not surprisingly, despite a mean age of 
less than 40 years, about 15% of patients suffered from medical diseases. Even more troubling is 
the possibility that smoking-related medical illnesses may become increasingly evident as the 
cocaine-abusing population grows older, as the risk of pulmonary and cardiovascular illnesses 
have been found to be associated with both duration and severity of smoking. (46,47) While we 
failed to find a difference in rates of medical diseases in the three groups, the absolute numbers 
of affected subjects was small, and the data on medical diseases were cross-sectional and 
obtained from chart review. Longitudinal studies may be required to clarify the extent to which 
substances of abuse interact with tobacco smoking to increase the risk for medical illnesses in a 
substance-dependent population. Contrary to our expectations, joint years of marijuana use were 
not correlated with number of medical symptoms. This might be because the population we 
studied was younger, most patients were not daily marijuana users, and the joint year history of 
marijuana (average 37 years) was not severe enough to observe possible relationships. For 
example, Fligiel et al. (48) found that cocaine users with an average of fifty joint years of 
marijuana use showed evidence of bronchial injury. Also, although we statistically controlled for 
tobacco use, we did not have a cocaine and marijuana group; therefore, the possibility of tobacco 
use as a possible confounder cannot be excluded. Additional findings from the study also deserve 
comment. The 79% prevalence of nicotine dependence in our sample attests to the widespread 
addiction to tobacco among cocaine-dependent patients and is consistent with published data in 
outpatient clinics. (49,50) Interestingly, there was no difference in the number of cigarettes 
smoked or severity of cocaine use between cocaine users who smoked tobacco and those who 
smoked both tobacco and marijuana. Cocaine use between those who only smoked crack and 
those who smoked crack and tobacco was also similar. Although the cross-sectional nature of 
data limits definitive conclusions, this seems to suggest tobacco use is not related to changes in 
cocaine use; likewise, marijuana use does not appear to be related to a reduction in tobacco or 
cocaine use. This additive pattern of use could also explain the higher medical symptoms in the 
tobacco and tobacco/marijuana groups. Finally, it is also important to note that cocaine abusers 
as a group had many medical complaints and endorsed an average of nearly 25 symptoms, 
attesting to the poor health of this population. This underscores the need for medical assessments 
to be an integral part of chemical dependency treatment programs. Our findings should be 
interpreted in light of certain methodological limitations. First, we studied self-reports of 
symptoms and did not collect physical examination and laboratory data. Though the MILCOM 
has been validated in psychiatric and non-psychiatric settings, 41 like other self-report 
instruments, it may be influenced by subjective factors such as perceptions about physical health 
and subject to recall bias. Second, because patients were recruited from a clinical program, a 
significant proportion abused other substances, particularly alcohol. While patients who were 
dependent on alcohol were excluded and we used statistical tests to control for alcohol use, it is 
possible that concurrent alcohol use might have affected the results. Third, we did not have a 
comparison group of cocaine and marijuana smokers because most of such patients invariably 
smoked tobacco. Such a group may have better clarified the relationship between cocaine, 
tobacco, and marijuana. Finally, the study was cross-sectional in nature; therefore, the 
directionality of relationships needs to be confirmed by longitudinal studies. In conclusion, our 
findings support a relationship between tobacco and marijuana smoking and medical problems 
among cocaine abusers. Also, neither marijuana use nor tobacco use appears to reduce cocaine 
use, and marijuana use does not seem to decrease tobacco use. Medical illnesses make the 
treatment of substance abusers complicated and expensive, a particular concern in today’s 
climate of cost-containment; therefore, cocaine treatment programs should effectively address 
both tobacco and marijuana use in their patients. Further research in this area should examine the 
relationship of drug use with objective assessments of health status to better understand the 
medical consequences of substance abuse. 
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